|
[Case] Case provides: Xiling Snow R Pharmaceutical is a company with 30 years experience in production enterprises, belonging to a group of companies started by the real estate. Company as a whole Sell Amount of less than 100 million yuan. Although with multiple product lines, but mostly common drug types. Marketing mode operation with investment. 2008, the company attending the stomach of a duodenal ulcer Traditional Chinese medicine P market, and hopes to become the market's rise in the core of drug species, and can this species, causing China to fight the best medicine Stomach Products, causing R medicine to fight "Tongxinluo." Reason have absolute confidence in this species, there are four main reasons: 1.P product is the last 3 years the only drugs approved in the stomach. By a University School of Medicine professor of experience in the treatment of ulcers based on the parties, after many years of theoretical research and clinical practice, careful development, the product with 20 years of national patent protection, and has excellent bactericidal, anti-inflammatory, analgesic acid suppression and repair of the wounds and other effects, more than 95% efficiency, which determines the P product with strong market competitiveness. 2. Corporate decision-making that, gastritis, gastric and duodenal ulcer incidence rates, consumer base, and there is recurrent, requiring long-term medication, the market capacity of large, foreign blockbuster product in the Los Stryker, OTC market, Start Time, all instructions in this market is huge. 3. In the competition, the stomach clinical market to Western-based, medicine less, in addition to Yangtze River Pharmaceutical Su grain varieties such as the stomach than 100 million yuan, nearly no competition. This growth is the product P, is simply a blue ocean. 4. In the country has been advocating the "Integrative Medicine" policy under the guidance of traditional Chinese medicine and Western medicine as a parallel, complementary medicine category, competition is not fierce, there are good opportunities for growth. Is to judge based on the above, R medicine full of confidence, very early planning for the 2009 marketing layout, hope to reach over 3 billion, five-year goal of over 300 million yuan. 1. The overall development of the "three-three-step" strategy, that is the first year to create market-based; the second year of a national incubator; the third year of a digestive medicine major brands. 2. Marketing model, hoping the way investment + self-employed, reserve supply, tries to form a national market layout. 3. Formed sales team prior to listing 100 people set up the marketing team to step up training ahead of the market of preparation. Trying to break through the terminal to achieve in 2009 into the 150 hospitals, plans to add 300 each year after the terminal layout of the hospital. 4. Do academic packaging products, including TECHNOLOGY, DA and so on. However, after a year of market operation, sales performance is not satisfactory. Analysis of down, for many reasons: First, in the market, with outstanding cardiovascular disease in Chinese medicine is different from the clinical end, sales and promotion of traditional Chinese medicines stomach seems to have birth defects, doctors are not enthusiastic. Prescription in the ulcer market portfolio, not make it go. Second, non- Health Insurance Status also affected the competitiveness of products; the three products in the terminal operation mode of the lack of clinical experience, professional academic promotion, from the structure to form, from content to the tool, have hastily launched the horse. But its underlying cause in the end is what? Market issues, product issues, or sales issues? Pharmaceutical R And how should I do? The e-commerce company in China offers quality products such as LED Underground Light , China Ceiling Light Fitting, and more. For more , please visit LED Spotlights Indoor today!
Related Articles -
LED Underground Light, China Ceiling Light Fitting,
|
